Navigation Links
2-step ovarian cancer immunotherapy made from patients' own tumor shows promise
Date:4/6/2013

WASHINGTON, D.C. As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

The immunotherapy has two steps a personalized dendritic cell vaccination and adoptive T-cell therapy. The team reports that in the study of 31 patients, vaccination therapy alone showed about a 61 percent clinical benefit, and the combination of both therapies showed about a 75 percent benefit.

The findings offer new hope for the large number of ovarian cancer patients who relapse following treatment. The first step of the immunotherapy approach is to preserve the patient's tumor cells alive, using sterile techniques at the time of surgery so they can be used to manufacture a personalized vaccine that teaches the patient's own immune system to attack the tumor. Then, the Penn Medicine team isolates immune cells called dendritic cells from patients' blood through a process called apheresis, which is similar to the process used for blood donation. Researchers then prepare each patient's personalized vaccine by exposing her dendritic cells to the tumor tissue that was collected during surgery.

Because ovarian cancer symptoms can be stealth and easily mistaken for other issues constipation, weight gain, bloating, or more frequent urination more than 60 percent of patients are diagnosed only after the disease has spread to their lymph nodes or other distant sites in the body, when treatment is much less likely to produce a cure compared to when the disease is detected early. As the fifth leading cause of cancer-related deaths among women in the United States, it takes the lives of more than 14,000 women each year.

"Given these grim outcomes, there is definitely a vast unmet need for the development of novel, alternate therapies," said lead author Lana Kandalaft, PharmD, PhD, MTR, a research assistant professor of Obstetrics and Gynecology and director of clinical development and operations in Penn Medicine's Ovarian Cancer Research Center. "This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer, and we believe the results are leading us toward a completely new way to treat this disease."

Both treatments are given in conjunction with bevacizumab, a drug that controls the blood vessel growth that feeds tumors. Combining bevacizumab with immunotherapy makes a powerful duo, Kandalaft says. The vaccine trial is still open to accrual to test new combinatorial strategies.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. 2-step immunotherapy attacks advanced ovarian cancer
3. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
4. U.S. Panel Rejects Ovarian Cancer Screening
5. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
6. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
7. The prevention of hereditary breast and ovarian cancer by PGD is feasible
8. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
9. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
10. Benefit of PET and PET/CT in ovarian cancer is not proven
11. Mechanisms of acquired chemoresistance in ovarian cancer identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... (PRWEB) , ... January 13, 2017 , ... ... Body and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of ... and Lounge notes that the many health and wellness benefits linked to a ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in Madrid ... expertly designed to meet the educational needs of European oncology clinicians and researchers who ... Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized by ...
(Date:1/13/2017)... ... January 13, 2017 , ... An inventor from Pahrump, Nev., used an unsavory medical experience to ... wear a Foley catheter and urine bag for a half year due to lazy bladder," ... that there should be a better way to do this." , He then designed and ...
(Date:1/13/2017)... ... January 13, 2017 , ... Friday, January 13 at 5 ... game room, increasing the size of the location to 90,000 square feet. , Included ... golf course that takes customers on an educational tour of the historic route, with ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s ... of colleges and schools of education across the country is urging a fundamental reconsideration ... of Principles released today, 175 deans sounded the alarm: “Our children suffer when we ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , announced that it ... Trust Co., Ltd. ("ZRT"). The Company signed ... Taihe Healthcare Fund in October 2016. The total amount of ...
(Date:1/13/2017)... 2017  Biologics Prescribers Collaborative (BPC) applauds ... for issuing final guidance calling for distinguishable ... is an important win for patients and ... pharmacovigilance, patient safety and transparency. ... FDA, we remain concerned with "random" suffixes called for ...
(Date:1/12/2017)... -- Cervical cancer test market in Asian region is growing ... declining women population, Japan has highest ... Indonesia is dominating in cervical cancer testing population ... rising sum of structured cervical cancer programs introduced by governments ... are some of the major growth drivers for the growth ...
Breaking Medicine Technology: